Molecular targets on blood vessels for cancer therapies in clinical trials

Keyphrases

• Blood Vessels 100%
• Clinical Trials 100%
• Cancer Therapy 100%
• Molecular Targets 100%
• Antivascular Therapy 80%
• Tumor 40%
• Small Molecules 40%
• Antiangiogenic Therapy 40%
• Ligand-based 40%
• Solid Tumors 20%
• Vascular Endothelial Growth Factor 20%
• Anti-angiogenesis 20%
• Tumor-associated 20%
• In Cancer 20%
• Fibronectin 20%
• Integrin 20%
• Angiogenesis Inhibitors 20%
• Proteoglycan 20%
• Matrix metalloproteinase-2 (MMP-2) 20%
• Antiangiogenic 20%
• Vasculature 20%
• Extracellular Proteins 20%
• Aminopeptidase N 20%
• Vascular Treatment 20%
• General Type 20%
• Vessel Structure 20%
• Extra Domain B 20%
• Prostate-specific Membrane Antigen 20%
• Target Molecules 20%
• Angiogenic Processes 20%
• Physical Difference 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Malignant Neoplasm 100%
• Clinical Trial 100%
• Molecular Target 100%
• Antiangiogenic Therapy 100%
• Vasculotropin 50%
• Solid Malignant Neoplasm 50%
• Neoplasm 50%
• Alanine Aminopeptidase 50%
• Receptor 50%
• Matrix Metalloproteinase 50%
• Integrin 50%
• Antiangiogenic 50%
• Proteoglycan 50%
• Fibronectin 50%
• Prostate Specific Membrane Antigen 50%
• Vascular Targeting Agent 50%